Well beyond tomorrow

About SynDermix Founded in 2009, SynDermix is a Swiss clinical-stage biotechnology company financed by private investors and with the intention to list on the SIX Swiss Exchange. We focus on developing ground-breaking treatments for disorders that affect the inner and outer skin of the human body (the mucosal barriers and skin tissues) where there is an unmet medical need.

Portfolio

Our portfolio is based on 3 proprietary technology platforms:

Plant lectins: SynDermix is the only clinical-stage company with a biopharmaceuticals pipeline dedicated to the development of therapeutic recombinant plant lectins

Nitric oxide: Our nitric oxide platform is based on a proprietary formulation with the potential to overcome the challenges of releasing and stabilising nitric oxide long enough for topical therapeutic use

Vibration therapies: Interfacing state-of-the-art MedTech with digital health, the medical devices in our vibration therapies platform provide drug-free, non-invasive treatments which relieve the disruptive symptoms of specific chronic conditions with currently no satisfactory standard of care

As a side-product pipeline, we additionally leverage our technology platforms to drive a wellcare pipeline of consumer health and beauty products of natural origin.

Business Model

Our business model is to a large extent virtual, driven by a framework of in-licensing, outsourcing and out-licensing:

� SynDermix identifies and acquires the rights to promising early-stage pipeline candidates with the potential to address unmet medical need

� We define our assets’ pipeline strategy by leveraging the complementary expertise of a seasoned executive team, a broad network of Key Opinion Leaders and contracted service providers

� We outsource the execution of our pipeline milestones to world-leading service providers, until a robust demonstration of the innovation (IP) and clinical value of our assets

� Once our pipeline candidates meet their value inflection point targets, we enter into corporate partnerships for commercialisation and market access

Management TeamDieter HemmerChief Executive OfficerCarlos Camozzi, MD, PhD, MBAClinical & RegulatoryKonstantinos Efthymiopoulos, PharmD, PhD, MBAMedical Marketing & Business DevelopmentJessica Kourniakti, DPhilStrategy & MarketingRolf Küng, MBAFinance & ControllingAnthony Lockett, MD, PhD, MBAResearch & Manufacturing

Board of DirectorsThomas Mehrling, MD, PhD ChairmanDieter HemmerDelegate of the BoardKevin P. Cox, PhDMember of the BoardHans Peter Frick, Dr. iur, LL.MMember of the BoardWolfgang Werlé, BAMember of the BoardHermann A. Wirz, BAMember of the Board

ContactSynDermix AGBuochserstrasse 26370 Stans, Switzerland

SynDermix Management AGVoltastrasse 618044 Zurich, Switzerland

Tel: +41 44 366 40 16Website: www.syndermix.chEmail: info@syndermix.ch

ISIN: CH0121242769

Member of

2018

-10

-31

UK BioIndustryAssociation

Well beyond tomorrow

Plant lectins pipeline according to indication

Vibration therapies, nitric oxide & wellcare pipelines

R&D Pre-Clinical Phase I Phase II Phase III Approval

Oral mucositis

Inflammatory bowel diseases

Pulmonary diseases (e.g. cystic fibrosis)

Skin diseases

Eye disorders

Cancer

Gastrointestinal ulceration

Wound healing (e.g. diabetic foot ulcers)

Cardiometabolic

R&D Pre-Clinical Phase I Phase II Phase III Approval

Chronic rhinosinusitis

Migraine

Wound healing

Wound healing

Other dermatological indications

Wellcare

SDX-1301

SDX-3101

SDX-13

SDX-3103

SDX-13

SDX-3104

SDX-13

SDX-2101

SDX-13

SDX-21

SDX-13/14

Énielle

SDX-13

SDX-14Accelerated reviewRegulatory strategy TBD

Our partners

Intellectual property & Regulatory

Keltie Intellectual property company, London

DanubiaPatent & law office, Budapest

Virtuoso LegalIntellectual property specialists, Leeds

Granzer Regulatory consulting & services, Munich

Manufacturing

Fujifilm Diosynth Biotechnologies Biotechnologies manu–facturer, Billingham, UK

CreaholicProfessional inventors, Biel CH

Preclinical/Clinical

BluTestMicrobiology CRO, Glasgow

Eurofins Scientific Worldwide laboratory testing services

CovanceGlobal CRO & drug development services

ISSIntegrated scientific services, Biel

Corporate & Commercial

Bihrer Attorneys at LawInternational & commercial lawyers, Zurich

BioScience Valuation Biotechnology company valuators & consultants, Grainau, DE

GfKMarket research company, London

SDX-13/14

Vision, mission and values

Our vision: To work in strategic partnerships to develop life-transforming treatments in areas of unmet medical need

Our mission: To become a global player in lasting innovation, to continually make a positive difference in the health and lives of patients worldwide

Values: We maintain a commitment to values which we believe foster successful teamwork and partnerships — to integrity, dedication and fairness — to innovation and to sustainability

Vibration therapies

Nitric oxide

Wellcare product